IP Library › Granted Patent US 12,247,024
Granted Patent B2
US 12,247,024 · App. 18/468,636 · Granted Mar 11, 2025

Process for preparing aficamten

Inventors: Denise Andersen (Montara, CA); Matthew Pfeiffer (Salt Lake City, UT); Norma Tom (Belmont, CA); Bradley P. Morgan (South San Francisco, CA)
Assignee: CYTOKINETICS, INC.
C07D413/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,247,024
App. No.
18/468,636
Granted
Mar 11, 2025
Kind
B2
Abstract

Provided herein is a process for the preparation of (R)—N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, intermediates thereof, and salts of the foregoing.

Claims (15)

1. A method of preparing a compound of Formula (1):

comprising:

(i) converting a compound of Formula (7)

to a compound of Formula (6)

by reacting the compound of Formula (7) with (R)-tert-butanesulfinamide;

(ii) converting the compound of Formula (6), to a compound of Formula (5)

by reacting the compound of Formula (6) with a reducing agent; and

(iii) converting the compound of Formula (5) to the compound of Formula (1).

2. The method of claim 1 , wherein reacting the compound of Formula (7) with (R)-tert-butanesulfinamide is performed in the presence of a Lewis acid.

3. The method of claim 1 , wherein reacting the compound of Formula (7) with (R)-tert-butanesulfinamide is performed in the presence of a water scavenger.

4. The method of claim 1 , wherein reacting the compound of Formula (7) with (R)-tert-butanesulfinamide is performed in the presence of titanium ethoxide.

5. The method of claim 1 , wherein reacting the compound of Formula (7) with (R)-tert-butanesulfinamide is performed in the presence of toluene at a temperature of between about 75° C. and about 85° C.

6. The method of claim 1 , wherein reacting the compound of Formula (6) with a reducing agent is performed in the presence of tetrahydrofuran at a temperature of between about −15° C. and about −5° C.

7. The method of claim 1 , wherein the reducing agent is sodium borohydride.

8. The method of claim 1 , wherein the compound of Formula (6) is used without work-up or purification.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2023
From: ANDERSEN, DENISE; PFEIFFER, MATTHEW; TOM, NORMA; MORGAN, BRADLEY P.
To: CYTOKINETICS, INC.
Reel/Frame 065841/0420 →
Continuity (3)
Continuation 17816898 · Aug 2, 2022
Provisional Application 63203888 · Aug 3, 2021
Related Publication 20240150336A1 · May 9, 2024
References Cited (26)
US 10836755B2 · Chuang et al. · 2020 [cited by applicant]
US 11472796B2 · Chuang et al. · 2022 [cited by applicant]
US 11932631B2 · Andersen · 2024 [cited by applicant]
US 12065436B2 · Chuang · 2024 [cited by applicant]
US 20060173183A1 · Powers · 2006 [cited by applicant]
US 20070155737A1 · Gallagher, Jr. et al. · 2007 [cited by applicant]
US 20080021024A1 · Sucholeiki et al. · 2008 [cited by applicant]
US 20080176870A1 · Nolte et al. · 2008 [cited by applicant]
US 20110028463A1 · Nozawa et al. · 2011 [cited by applicant]
US 20200277262A1 · Jones et al. · 2020 [cited by applicant]
US 20220315571A1 · Tom et al. · 2022 [cited by applicant]
US 20230045450A1 · Andersen et al. · 2023 [cited by applicant]
US 20230119665A1 · Chuang et al. · 2023 [cited by applicant]
CN 114835687A · 2022 [cited by applicant]
WO 2006083454A1 · 2006 [cited by applicant]
WO 2021011807A1 · 2021 [cited by applicant]
WO 2022172037A1 · 2022 [cited by applicant]
WO 2023040830A1 · 2023 [cited by applicant]
WO 2024134498A1 · 2024 [cited by applicant]
WO 2024179422A1 · 2024 [cited by applicant]
WO 2024182469A1 · 2024 [cited by applicant]
CAS SciFinder. (Nov. 30, 2023). “Reactions. Task History. 31-614-CAS-35984908,” SciFinder, 4 pages. [cited by applicant]
International Search Report and Written Opinion, mailed on Oct. 28, 2022, for PCT Application No. PCT/US2022/074427, filed on Aug. 2, 2022, 13 pages. [cited by applicant]
Cremin, P. et al. (Oct. 25, 2022). “In Vivo Pharmacokinetic Characterization of CK-3773274, a Novel Cardiac Myosin Inhibitor,” American Association of Pharmaceutical Scientists ePoster Library [Online], 1 page. [cited by applicant]
International Preliminary Report on Patentability issue date of Feb. 6, 2024, for Patent Application No. PCT/US2022/074427, filed Aug. 2, 2022, 7 pages. [cited by applicant]
U.S. Appl. No. 18/762,390, filed Jul. 2, 2024, for Chuang Chihyuan et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.). [cited by applicant]
Cited By (1)
US 12,370,179